Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer By Ogkologos - December 19, 2025 442 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an updated analysis of the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Record Impact Factor for Annals of Oncology Highlights Growing Influence of... July 2, 2026 Camonsertib in Patients with Advanced Solid Tumours Harbouring Loss of Function... July 3, 2023 Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated... April 13, 2026 Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance December 4, 2025 Load more HOT NEWS A Peripheral Immune Signature of Responsiveness to PD-1 Blockade in cHL GreaterGood Is Donating Thousands of Masks to Help Animal Shelters Stay... From Scan to Scan: The Challenges of Living with Metastatic Cancer EMA Recommends Granting a Marketing Authorisation for Zanubrutinib for the Treatment...
